Galvus Met Tablets (Vildagliptin + Metformin) | Eucreas | Effective Type 2 Diabetes Control
Galvus Met Tablets (Vildagliptin + Metformin) are used to treat type 2 diabetes mellitus by improving glycemic control. Vildagliptin and Metformin are active ingredients that belong to a class of anti-diabetic.
Product Overview
Galvus Met is a medication used to treat type 2 diabetes. It is a combination of two active ingredients, Vildagliptin and Metformin. Vildagliptin is a type of medication known as a dipeptidyl peptidase-4 (DPP-4) inhibitor. By combining these two distinct agents, the medication provides a powerful dual-action approach to glycemic control. It helps the pancreas produce more insulin when blood sugar levels are high and reduces the excessive production of sugar by the liver. This comprehensive treatment plan is essential for maintaining stable glucose levels and preventing the long-term health complications associated with diabetes.
Product Composition
- Vildagliptin: 50 mg
- Metformin Hydrochloride: 500 mg / 850 mg / 1000 mg
- Core Excipients: Hydroxypropyl cellulose, Magnesium stearate, Talc
- Coating: Hypromellose, Titanium dioxide, Polyethylene glycol, Iron oxide
Product Specification
| Feature | Details |
| Therapeutic Class | Oral Anti-diabetic Combination |
| Active Components | Vildagliptin + Metformin |
| Formulation | Film-coated tablet |
| Administration | Oral |
| Primary Indication | Type 2 Diabetes Mellitus |
Mechanism of Action
- DPP-4 Inhibition: Vildagliptin blocks the DPP-4 enzyme, which increases levels of incretin hormones. These hormones signal the pancreas to release insulin only when blood sugar is high.
- Glucagon Suppression: By increasing incretin levels, Vildagliptin also reduces the secretion of glucagon, a hormone that causes the liver to produce more sugar.
- Sensitivity Improvement: Metformin works by making the body’s cells more sensitive to insulin, allowing them to remove sugar from the blood more efficiently.
- Liver Glucose Regulation: Metformin significantly decreases the amount of glucose the liver produces and releases into the bloodstream.
- Balanced Control: The combined effect ensures that blood sugar is managed both during fasting periods and after meals.
Key Benefits
- Comprehensive Sugar Control: Addresses both insulin production and insulin resistance in one tablet.
- Reduced Pill Burden: Combines two essential therapies, making it easier to follow a daily treatment schedule.
- Enhanced Safety Profile: Features a lower risk of hypoglycemia (low blood sugar) compared to traditional sulfonylurea drugs.
- Effective HbA1c Management: Helps patients achieve and maintain their long-term blood sugar targets effectively.
- Weight Management Support: Generally considered weight-neutral, meaning it does not typically lead to the weight gain associated with other diabetes drugs.
- Targeted Delivery: Works specifically when the body needs it most, such as after eating, to prevent dangerous glucose spikes.
Precautions
Important precautions for Galvus Met Tablets (Vildagliptin + Metformin)
Blood sugar monitoring precautions
- Regular monitoring of blood glucose levels is essential
- Risk of hypoglycemia when combined with insulin or sulfonylureas
- Do not skip meals while on therapy
- Dosage adjustments should only be done under medical supervision
Kidney and liver safety precautions
- Not recommended in severe kidney impairment due to metformin risk
- Liver function should be monitored during long-term use
- Dose adjustment may be required in mild to moderate renal issues
- Dehydration should be avoided to reduce kidney strain
Lifestyle and diet precautions
- Maintain a balanced diet with controlled carbohydrate intake
- Avoid excessive alcohol consumption due to lactic acidosis risk
- Stay well hydrated during treatment
- Follow regular exercise routine as advised
Special population precautions
- Elderly patients require closer monitoring for kidney function
- Not suitable for type 1 diabetes or diabetic ketoacidosis
- Pregnant or breastfeeding women should use only if clearly advised
- Use cautiously in patients with heart disease
Safety overview table
| Area of caution | Precaution guidance |
|---|---|
| Kidney function | Avoid in severe impairment, monitor regularly |
| Blood sugar control | Regular monitoring to prevent hypo/hyperglycemia |
| Alcohol intake | Avoid due to lactic acidosis risk |
| Special populations | Elderly, pregnant, and cardiac patients need supervision |
Usage
Dosage
Dosage is tailored by your healthcare provider based on your current blood glucose levels and previous treatment history. The following table provides the standard dosing frequency.
| Status | Recommended Frequency | Maximum Daily Dose |
| Standard Treatment | 1 tablet twice daily | 100 mg Vildagliptin / 2000 mg Metformin |
| Starting Dose | 1 tablet (50/500 mg) twice daily | Adjusted based on tolerance |
| Switching Therapy | Based on current Metformin dose | Monitored by a specialist |
Administration
Timing: For best results, take one tablet in the morning and one in the evening.
With Food: Always take the tablet during or immediately after a meal to reduce the risk of gastrointestinal discomfort.
Swallow Whole: Do not crush, chew, or break the tablets. Swallow them whole with a glass of water.
Consistency: Take your doses at the same time every day to keep your blood sugar levels steady.
Missed Dose: If you miss a dose, take it with your next meal unless it is nearly time for your next scheduled dose. Never double the dose.
Monitoring: Regular monitoring of kidney and liver function is recommended during treatment.
Uses
Type 2 Diabetes Management: Specifically indicated for the improvement of glycemic control in adults when diet and exercise alone are insufficient.
Metformin Non-Responders: Used when Metformin alone does not provide adequate blood sugar control.
Combination Therapy Replacement: Can be used to replace separate tablets of Vildagliptin and Metformin for easier daily management.
Post-Meal Glucose Control: Effectively targets and reduces high blood sugar spikes that occur after eating.
Fasting Blood Sugar Regulation: Helps maintain lower, more stable glucose levels during periods of fasting or sleep.
Long-Term Complication Prevention: By maintaining target HbA1c levels, it helps reduce the risk of diabetic neuropathy (nerve damage), nephropathy (kidney damage), and retinopathy (eye damage).
Side effects
Common side effects
- Nausea or vomiting
- Diarrhea or loose stools
- Abdominal discomfort or bloating
- Headache or dizziness
Metformin related effects
- Metallic taste in mouth
- Loss of appetite
- Vitamin B12 deficiency with long-term use
- Gastrointestinal upset during initial treatment
Vildagliptin related effects
- Mild tremor or fatigue
- Dizziness in some individuals
- Swelling in rare cases
- Upper respiratory tract infections
Less common side effects
- Skin rash or itching
- Joint pain
- Mild hypoglycemia (more likely with other diabetes medicines)
- Increased sweating
Serious side effects (rare)
- Severe hypoglycemia when combined with other agents
- Lactic acidosis (rare but serious, linked to metformin)
- Severe allergic reactions
- Pancreatitis (very rare)
Side effects summary table
| System affected | Possible reaction |
|---|---|
| Gastrointestinal | Nausea, diarrhea, abdominal discomfort |
| Metabolic | Lactic acidosis (rare), hypoglycemia |
| Nervous system | Dizziness, headache, fatigue |
| Skin | Rash, itching |
| Nutritional | Vitamin B12 deficiency (long-term use) |
FAQs
Q: What is the product used for?
A: Galvus Met treats Type 2 Diabetes. It uses two medicines to lower blood sugar. This helps prevent future health problems like kidney damage or blindness.
Q: How should I take this medication?
A: Take your tablet with or just after food. This helps prevent an upset stomach. Most people take one tablet in the morning and one in the evening.
Q: Can it cause low blood sugar (hypoglycemia)?
A: This medicine has a low risk of causing low blood sugar. However, the risk increases if you also take other diabetes drugs. Always carry a sugary snack just in case.
Q: What should I do if I miss a dose?
A: Take it as soon as you remember with a meal. If it is almost time for your next dose, skip the missed one. Never take two tablets to make up for a missed dose.
Q: Are there any common side effects?
A: You may feel nauseous, dizzy, or experience a metallic taste. Some users report diarrhea or stomach pain. These symptoms usually go away as your body adjusts.
Q: Can I drink alcohol while on Galvus Met?
A: You should limit or avoid alcohol while taking this medicine. Alcohol increases the risk of low blood sugar. It can also lead to a rare but serious condition called lactic acidosis.
Q: Do I still need to diet and exercise?
A: Yes, this medication works best with a healthy lifestyle. Continue your doctor-recommended diet and exercise plan. Regular physical activity helps the medicine work more effectively.
Interactions
Drug interactions of Galvus Met Tablets (Vildagliptin + Metformin)
Antidiabetic medicines
- Insulin and sulfonylureas may increase risk of hypoglycemia
- Other oral antidiabetic drugs may require dose adjustment
- Combination therapy increases need for regular blood glucose monitoring
- SGLT2 inhibitors or GLP1 agonists may enhance glucose lowering effect
Metformin related interactions
- Iodinated contrast agents may increase risk of kidney complications and lactic acidosis
- Alcohol increases risk of lactic acidosis and should be avoided
- Cimetidine may increase metformin levels in blood
- Certain diuretics may affect renal function and glucose control
Vildagliptin related interactions
- Drugs affecting liver enzymes may alter vildagliptin metabolism
- Other incretin-based therapies may increase overlapping effects
- Strong enzyme inducers may reduce efficacy in some cases
Condition based interactions
- Kidney impairment increases risk of metformin accumulation
- Liver disease may affect drug safety and metabolism
- Dehydration increases risk of adverse effects
- Severe infections or surgery may require temporary discontinuation
Drug interactions table
| Drug class | Interaction effect |
|---|---|
| Insulin and sulfonylureas | Increased risk of hypoglycemia |
| Iodinated contrast media | Risk of kidney injury and lactic acidosis |
| Alcohol | Increased risk of lactic acidosis |
| Diuretics | Possible kidney function and glucose impact |
| Cimetidine | Increased metformin concentration |
| Manufacturer | : | Cipla Pharma, India |
| Trade Name | : | Eucreas |
| Generic Search | : | Metformin + Vildagliptin |
| Strength | : | 50mg+ 500mg, 50mg+ 850mg, 50mg +1000mg. |
Latest Products
